Small molecule · Inhibitor of mechanistic target of rapamycin (mTOR) (MTOR) · developed by Palvella Therapeutics
PTX-022 is a topical gel containing sirolimus (rapamycin). After application, sirolimus enters basal keratinocytes and forms a complex with FKBP-12 that inhibits mTOR and mTOR-mediated signaling, reducing proliferation. It is studied in pachyonychia congenita.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05643872 | Phase 3 | Pachyonychia Congenita | Recruiting | PVLA |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Pachyonychia Congenita
Updated Oct 25, 2026. Something wrong or missing? Report it on the PVLA page.
See PVLA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
PVLA catalysts and pipeline →